PubRank

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Clinical Trial ID NCT01400451

PubWeight™ 49.69‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01400451

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012 5.15
2 Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012 3.09
3 Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014 2.12
4 Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013 2.03
5 The role of BRAF V600 mutation in melanoma. J Transl Med 2012 2.00
6 Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011 1.97
7 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
8 Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014 1.79
9 CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013 1.71
10 The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P T 2013 1.68
11 Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 2013 1.61
12 Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012 1.60
13 Melanoma: new insights and new therapies. J Invest Dermatol 2012 1.54
14 Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014 1.47
15 Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J 2012 1.18
16 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
17 Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012 1.16
18 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
19 Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 2013 1.04
20 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
21 Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012 0.97
22 Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 2013 0.94
23 New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013 0.92
24 Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther 2014 0.92
25 Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res 2012 0.91
26 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
27 Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology 2012 0.87
28 Targeting BRAF in melanoma: biological and clinical challenges. Crit Rev Oncol Hematol 2013 0.87
29 Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 2012 0.87
30 Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochem Res Int 2014 0.86
31 Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine. Sci Adv 2015 0.85
32 Latest approved therapies for metastatic melanoma: what comes next? J Skin Cancer 2013 0.80
33 Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med 2012 0.80
34 Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother 2011 0.80
35 Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. J Transl Med 2013 0.79
36 MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther 2015 0.77
37 Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids. Melanoma Res 2013 0.75
38 What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma? Immunotherapy 2012 0.75
39 Malignant Melanoma. Healthcare (Basel) 2013 0.75
Next 100